You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Colorcon
Johnson and Johnson
Harvard Business School
Express Scripts

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Momelotinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Momelotinib?

Momelotinib is an investigational drug.

There have been 14 clinical trials for Momelotinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Thrombocytosis, Thrombocythemia, Essential, and Primary Myelofibrosis. The leading clinical trial sponsors are Gilead Sciences, Sierra Oncology, Inc., and Fred Hutchinson Cancer Research Center.

There are three hundred and thirty-four US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Momelotinib
TitleSponsorPhase
A Phase 3 Study Comparing the Activity of Momelotinib in Symptomatic and Anemic Myelofibrosis Patients Versus DanazolSierra Oncology, Inc.Phase 3
Extended Access of Momelotinib in Adults With MyelofibrosisGilead SciencesPhase 2
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Gilead SciencesPhase 2

See all Momelotinib clinical trials

Clinical Trial Summary for Momelotinib

Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib

See all Momelotinib clinical trials

US Patents for Momelotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Momelotinib   Get Started for $10 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Get Started for $10
Momelotinib   Get Started for $10 Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA)   Get Started for $10
Momelotinib   Get Started for $10 Bicyclic bromodomain inhibitors Zenith Epigenetics Ltd. (Calgary, AB, CA)   Get Started for $10
Momelotinib   Get Started for $10 Methods for the treatment of HER2 amplified cancer Pharmacyclics LLC (Sunnyvale, CA)   Get Started for $10
Momelotinib   Get Started for $10 Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA)   Get Started for $10
Momelotinib   Get Started for $10 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Get Started for $10
Momelotinib   Get Started for $10 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (Cambridge, MA)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Momelotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Momelotinib Australia AU2015244171 2034-04-11   Get Started for $10
Momelotinib Australia AU2015244179 2034-04-11   Get Started for $10
Momelotinib Canada CA2945128 2034-04-11   Get Started for $10
Momelotinib Canada CA2945129 2034-04-11   Get Started for $10
Momelotinib China CN106414451 2034-04-11   Get Started for $10
Momelotinib China CN106459063 2034-04-11   Get Started for $10
Momelotinib European Patent Office EP3129377 2034-04-11   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.